Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives

Core Tip

Core Tip: Han et al’s multicenter trial demonstrates vonoprazan triple therapy’s superior efficacy over standard bismuth quadruple therapy for Helicobacter pylori eradication in China, successful nationwide implementation faces critical challenges. Key barriers include limited drug accessibility in primary healthcare settings, higher costs compared to traditional therapies, and significant regional variations in antibiotic resistance patterns across China’s diverse population. The study’s single-province design cannot fully represent national applicability. Addressing these implementation gaps through comprehensive health system research, cost-effectiveness analyses, and multi-regional validation studies is essential for translating these promising clinical findings into improved patient outcomes across China’s heterogeneous healthcare landscape.